3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
19
Lung Neoplasms
18
Breast Neoplasms
12
Multiple Myeloma
10
Carcinoma, Non-Small-Cell Lung
9
Leukemia, Myeloid, Acute
8
Rectal Neoplasms
7
Carcinoma, Hepatocellular
7
Myelodysplastic Syndromes
6
Mouth Neoplasms
6
Sarcoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Pancreatic Neoplasms
5
Oropharyngeal Neoplasms
5
Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Myelomonocytic, Chronic
5
Head and Neck Neoplasms
5
Brain Neoplasms
5
Ovarian Neoplasms
4
Melanoma
4
Lymphoma, B-Cell
4
Leukemia, Biphenotypic, Acute
4
Glioma
4
Fallopian Tube Neoplasms
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Lymphoma, T-Cell
3
Lymphoma, Non-Hodgkin
3
Laryngeal Neoplasms
3
Interventions
Radiotherapy
8
Doxorubicin
7
pazopanib
5
palbociclib
4
Trabectedin
4
Gemcitabine
4
ribociclib
3
pembrolizumab
3
eribulin
3
selinexor
2
liposomal doxorubicin
2
avelumab
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Ifosfamide
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
sotigalimab
1
sodium thiosulfate
1
sitravatinib
1
silmitasertib
1
sargramostim
1
romidepsin
1
regorafenib
1
plitidepsin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liposarcoma
×
X-Rays
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled